Cost-effectiveness of a 21-gene recurrence score assay versus Canadian clinical practice in women with early-stage estrogen- or progesterone-receptor-positive, axillary lymph-node negative breast cancer

被引：0
作者：
Malek B Hannouf
Bin Xie
Muriel Brackstone
Gregory S Zaric
机构：
[1] University of Western Ontario,Department of Epidemiology and Biostatistics. Schulich School of Medicine and Dentistry
[2] University of Western Ontario,Department of Obstetrics & Gynaecology, Schulich School of Medicine and Dentistry
[3] University of Western Ontario,Department of Oncology, Schulich School of Medicine and Dentistry
[4] University of Western Ontario,Department of Surgery, Schulich School of Medicine and Dentistry
[5] University of Western Ontario,Richard Ivey School of Business
来源：
BMC Cancer | / 12卷
关键词：
Breast cancer; Chemotherapy; Cost-effectiveness; 21-gene recurrence score assay;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 302 条
  • [1] Ghafoor A(2003)Trends in breast cancer by race and ethnicity CA Cancer J Clin 53 342-355
  • [2] Jemal A(2001)Side effects of adjuvant treatment of breast cancer N Engl J Med 344 1997-2008
  • [3] Ward E(1998)The relationship between prognostic and predictive factors in the management of breast cancer Breast Cancer Res Treat 52 261-288
  • [4] Cokkinides V(1998)Assessing the clinical impact of prognostic factors: when is "statistically significant" clinically useful? Breast Cancer Res Treat 52 305-319
  • [5] Smith R(2004)A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer N Engl J Med 351 2817-2826
  • [6] Thun M(2005)Tumor gene expression and prognosis in breast cancer patients with 10 or more positive lymph nodes Clin Cancer Res 11 8623-8631
  • [7] Shapiro CL(2006)Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer J Clin Oncol 24 3726-3734
  • [8] Recht A(2008)Trial assessing individualized options for treatment for breast cancer: the TAILORx trial Future Oncol 4 603-610
  • [9] Henderson IC(2010)Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: results from NSABP B-14 and NSABP B-20 J Clin Oncol 28 1677-1683
  • [10] Patek AJ(2010)Health economics in drug development: efficient research to inform healthcare funding decisions Eur J Cancer 46 2674-2680
12345678910